Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Cabot Corp (CBT) Q3 Earnings Miss Estimates, Revenues Beat

Published 08/04/2017, 08:50 AM
Updated 07/09/2023, 06:31 AM
Cabot Corporation (NYSE:CBT) recorded net earnings (attributable to shareholders) of $45 million or 71 cents per share for the third quarter of fiscal 2017 (ended Jun 30, 2017) compared with $56 million or 88 cents recorded a year ago.
Barring one-time items, the adjusted earnings for the reported quarter were 81 cents per share, missing the Zacks Consensus Estimate of 85 cents.
Revenues increased around 13.5% year over year to $705 million in the reported quarter. Sales beat the Zacks Consensus Estimate of $661 million.
Cabot Corporation Price, Consensus and EPS Surprise
Reinforcement Materials sales in the reported quarter rose 36% year over year to $367 million.
Sales from the Performance Chemicals remained almost flat year over year at $229 million in the reported quarter.
Sales from the Purification Solutions fell 7.8% year over year to $71 million.
Sales from the Specialty Fluids fell to $12 million in the reported quarter from $19 million reported in the year-ago quarter.
Financial Position
Cabot Corp. ended the fiscal third quarter with cash and cash equivalents of $198 million.
The company’s long-term debt was $665 million as of Jun 30, 2017.
Cash provided by operating activities were around $132 million for the fiscal third quarter.
Outlook
Cabot Corp. believes that Reinforcement Materials segment will continue to impress, although the company is expected to see modestly higher fixed costs in the fourth quarter. The end markets in Performance Chemicals are anticipated to remain strong and the segment’s volumes and product mix are expected to improve with the resolution of the unplanned downtime. Purification Solutions is expected to gain from seasonal volume growth and lower fixed costs in the fourth quarter. The company remains focused on delivering shareholder value by growing annual adjusted earnings per share by 7–10% over time.
Price Performance
Cabot Corp.’s shares fell around 4% over the last three months, underperforming the industry’s 1.8% gain.
Zacks Rank & Key Picks
Cabot Corp. currently carries a Zacks Rank #4 (Sell).
Some better-ranked companies in the chemical space include Akzo Nobel N.V. (OTC:AKZOY) , BASF SE (OTC:BASFY) and Hitachi Chemical HCHMY. All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Akzo Nobel has an expected long-term earnings growth of 11.1%.
BASF has an expected long-term earnings growth of 8.6%.
Hitachi Chemical has an expected long-term earnings growth of 5%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained
+18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>


BASF SE (BASFY): Free Stock Analysis Report

Cabot Corporation (CBT): Free Stock Analysis Report

Akzo Nobel NV (AKZOY): Free Stock Analysis Report

HITACHI CHEMICL (HCHMY): Free Stock Analysis Report

Original post
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.